This multidisciplinary expert panel opinion on bacteriophage therapy has been written in the context of a society that is confronted with an ever‐increasing number of antibiotic resistant bacteria. To avoid the return to a pre‐antibiotic era, alternative treatments are urgently needed. The authors aim to contribute to the opinion formation of relevant stakeholders on how to potentially develop an infrastructure and legislation that paves the way for the acceptance and re‐implementation of bacteriophage therapy. Today's society is confronted with an ever‐increasing number of antibiotic resistant bacteria. To avoid the return to a pre‐antibiotic era, alternative treatments are urgently needed. Bacteriophage therapy is accepted and practiced in parts of Eastern Europe. However, agreement has yet to be made in the rest of the world on how to overcome hurdles and how to establish a functional and practical legal frame‐work that is flexible enough to exploit and further explore the specificity of bacteriophages as an antibacterial, while giving precedence to patient safety. This paper aims to contribute to the opinion formation of relevant stakeholders on how to potentially develop an infrastructure and legislation that paves the way for the acceptance and re‐implementation of bacteriophage therapy. (Idea and design: Ville Friman)